Sun Pharma Q1FY23: Beats expectations, but with a scope for improvement
Sun Pharma is trading at 27 times FY23 expected earnings, which is closer to its historical range02-08-2022
02-08-2022
Pharma Inc gets back to life beyond Covid
For Sun Pharma, its investment in speciality business is paying off, as it is becoming a driver of growth for the company's US business. Cipla's 'One India' strategy, focusing on branded prescription, trade generics and consumer health brands, is leading to continued core portfolio momentum across businesses.01-08-2022
Sun Pharma stock likely to keep shining amid global specialty scale-up
Focus on key markets to help expand branded formulations business, say experts01-08-2022
Results Earnings Call for Q1FY23 of Sun Pharmaceutical Industries
Conference Call with Sun Pharmaceutical Industries Management and Analysts on Q1FY23 Performance and Outlook. Listen to the full earnings transcript.31-07-2022
We continue to increase our reach and access in India, say Sun Pharma execs
Senior Sun Pharma executives speak on a two-pronged strategy for the China market, beginning R&D of biosimilar products, and more31-07-2022
SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Investor call audio recording29-07-2022
Sun Pharma shares jump over 5% after firm's Q1 net profit rises 43%
Shares of Sun Pharma on Friday jumped over 5 per cent after the company reported a 43 per cent rise in consolidated net profit for the June quarter. The stock climbed 5.45 per cent to settle at Rs 943.55 apiece on the BSE. During the day, it rallied 6.31 per cent to Rs 951.25. On the NSE, it jumped 5.44 per cent to Rs 943.60 apiece. In volume terms, 4.88 lakh shares were traded on the BSE and over 1.13 crore shares on the NSE during the day. On Friday, Sun Pharma reported a 43 per cent rise in consolidated net profit at Rs 2,061 crore for the June quarter, riding on robust sales across markets. The Mumbai-based company had posted a net profit of Rs 1,444 crore in April-June period of 2021-22. Total revenue from operations rose to Rs 10,762 crore in the period under review from Rs 9,719 crore earlier, Sun Pharmaceutical Industries said in a regulatory filing. The 30-share BSE barometer jumped 712.46 points or 1.25 per cent to settle at 57,570.25.29-07-2022
Q1FY23 Quarterly Result Announced for Sun Pharmaceutical Industries Ltd.
Sun Pharmaceutical Industries Announced Q1FY23 Result : Q1 Gross Sales at Rs. 106,440 million up 10.1% YoY Q1 Net Profit at Rs. 20,609 million up 42.7% YoY Gross sales at Rs. 106,440 million, growth of 10.1% over Q1 last year. Excluding Covid products sales for Q1 last year, overall sales are up by about 14% India formulation sales at Rs. 33,871 million, up 13% on like-to-like basis, excluding Covid products sales of Q1 last year. On reported basis, the growth is 2.4% over Q1 last year US formulation sales at US$ 420 million, growth of 10.7% over Q1 last year Emerging Markets formulation sales at US$ 245 million, up by 12.6% over Q1 last year Rest of World formulation sales at US$ 190 million, up by 2.6% over same quarter last year R&D; investments at Rs. 4,608 million compared to Rs. 5,926 million for Q1FY22 EBITDA at Rs. 28,844 million (including other operating revenues), with EBITDA margin at 26.8% Net profit for the quarter was at Rs. 20,609 million, up by 42.7% YoY. Excluding the exceptional items of Q1 last year, adjusted net profit was up by 4.1%. Production Linked Incentive (PLI) scheme – will help in further improving technology capabilities, capacity utilization and competitiveness. Dilip Shanghvi, Managing Director of the Company said, “For Q1, all our businesses recorded good growth, driven by a combination of sustained scale-up for our specialty business and all-round growth across markets. Specialty business has grown by 29% driven by Ilumya, Cequa, Odomzo and Winlevi. Our India business continues to grow faster than market, leading to increase in market share. We have been able to report healthy margins despite rising costs. We continue to focus on expanding our global specialty business, growing all our businesses and improving our market share.” Result PDF29-07-2022
SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Press Release relating to financial results for the first quarter ending June 30th, 2022.29-07-2022
SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Financial Results For The Quarter Ended June 30, 2022
With reference to the intimation of Board meeting submitted on July 12, 2022, we wish to inform you that the Meeting of the Board of Directors of the Company was held today i.e. July 29, 2022 which commenced at 10:00 a.m. IST and ended at 01:25 p.m. IST. The Board has, inter-alia, approved Unaudited Standalone and Consolidated Financial Results for the quarter ended June 30, 2022.29-07-2022